Cardiology

Episodes 1-16 of 97

- Michael Miller, MD, FACC, FAHA, FNLA
  Peer
- Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
  Peer
- Aruna Pradhan, MD, MPH
  Peer
- James A. Underberg, MD
  Peer
3
CME/CE Meeting
CME/CE Meeting
Adopting the New Therapeutic “LineUp” t…
Sarasota, Florida
February 04, 2022
07:45 AM - 12:00 PM EST
3.50 creditsLearn more
- Karol Watson, MD, PhD
  Peer
- Joseph Saseen, PharmD, BCPS, BCACP, CLS
  Peer
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Charles P. Vega, MD
  Peer
3
CME/CE Meeting
CME/CE Meeting
Adopting the New Therapeutic “Lineup” t…
San Jose, California
March 19, 2022
07:45 AM - 12:00 PM PDT
3.50 creditsLearn more
2
CME/CE Meeting
CME/CE Meeting
Adopting the New Therapeutic “Lineup” t…
Houston, Texas
April 04, 2022
05:15 PM - 09:30 PM CDT
3.50 creditsLearn more
- Murray Epstein, MD
  Peer
- Gates B. Colbert, MD, FASN
  Peer
0
CME/CE
Considerations When Using a Potassium Binder in Patients with CKD
Considerations When Using a Potassium Binder in Patients with CKD
0.25 credits
Considerations When Using a Potassium Binder in Patients with CKD
0.25 credits
- Peter van der Meer, MD, PhD
  Peer
- Pieter Martens, MD, PhD
  Peer
1
CME/CE
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
0.25 credits
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remode…
0.25 credits
- Peter Rossing, DMSc, MD
  Peer
- Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
  Peer
- Matthew R. Weir, MD
  Peer
1
CME/CE
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
0.25 credits
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
0.25 credits
- Peter Libby, MD
  Peer
- Lawrence A. Leiter, MD
  Peer
- Prof. Kausik Ray, MBChB, MD, MPhil
  Peer
1
CME/CE
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
0.25 credits
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASC…
0.25 credits
- Mikhail Kosiborod, MD
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Matthew R. Weir, MD
  Peer
1
CME/CE
Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Patient Outcomes
Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Patient Outcomes
0.50 credits
Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Pa…
0.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Piotr Ponikowski, MD, PHD, FESC, FHFA
  Peer
1
Global Heart Failure Academy
Clinical Implications of ESC/HFA Guideline Updates for Iron Deficiency in Heart Failure
Clinical Implications of ESC/HFA Guideline Updates for Iron Deficiency in Heart Failure
Clinical Implications of ESC/HFA Guideline Updates for Iron Deficiency in Heart…
- Gregg C. Fonarow, MD
  Peer
- Andrew J. S. Coats, MD
  Peer
1
CME/CE
Applying Key Updates from ESC/HFA to Managing Heart Failure
Applying Key Updates from ESC/HFA to Managing Heart Failure
0.25 credits
Applying Key Updates from ESC/HFA to Managing Heart Failure
0.25 credits
- Keith C. Ferdinand, MD
  Peer
- Marco Metra, MD
  Peer
6
CME/CE
Managing HK in HF: Navigating the Evolving Clinical Landscape
Managing HK in HF: Navigating the Evolving Clinical Landscape
0.25 credits
Managing HK in HF: Navigating the Evolving Clinical Landscape
0.25 credits
- Mikhail Kosiborod, MD
  Peer
- Ewa A. Jankowska, MD, PhD, FESC
  Peer
- Phil McEwan, PhD
  Peer
1
CME/CE
Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact
Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact
0.25 credits
Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeco…
0.25 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
2
CME/CE
From Guidelines to Practice: Key Updates From 2021 HFSA
From Guidelines to Practice: Key Updates From 2021 HFSA
0.25 credits
From Guidelines to Practice: Key Updates From 2021 HFSA
0.25 credits
- Robert J. Chilton, DO
  Peer
- John R. Nelson, MD, FACC, FNLA, FASNC
  Peer
4
CME/CE
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
1.00 credits
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
1.00 credits
- Ileana L. Piña, MD, MPH, FAHA, FACC
  Peer
- Javed Butler, MD, MBA, MPH
  Peer
- Gregg C. Fonarow, MD
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
3
CME/CE
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
1.50 credits
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities t…
1.50 credits
- Javed Butler, MD, MBA, MPH
  Peer
- Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
7
CME/CE
A New Normal? COVID-19 and HF in Clinical Trials
A New Normal? COVID-19 and HF in Clinical Trials
0.25 credits
A New Normal? COVID-19 and HF in Clinical Trials
0.25 credits